Bicocca Open Archive

Logo unimib boa
ZAMBELLI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 14.717
NA - Nord America 5.866
EU - Europa 3.405
SA - Sud America 2.210
AF - Africa 245
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 26.454
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 6.425
US - Stati Uniti d'America 5.484
SG - Singapore 3.134
CN - Cina 2.064
BR - Brasile 1.673
IT - Italia 1.510
HK - Hong Kong 1.183
BD - Bangladesh 633
RU - Federazione Russa 477
KR - Corea 303
DE - Germania 300
FR - Francia 292
IN - India 201
CA - Canada 199
AR - Argentina 178
ID - Indonesia 137
FI - Finlandia 129
IQ - Iraq 121
SE - Svezia 120
GB - Regno Unito 113
EC - Ecuador 105
MX - Messico 103
IE - Irlanda 84
UA - Ucraina 78
ZA - Sudafrica 78
PK - Pakistan 77
CO - Colombia 73
TR - Turchia 73
AT - Austria 64
NL - Olanda 62
PY - Paraguay 60
PH - Filippine 48
SA - Arabia Saudita 48
UZ - Uzbekistan 44
JP - Giappone 43
CL - Cile 40
VE - Venezuela 40
ES - Italia 38
MA - Marocco 37
TN - Tunisia 30
MY - Malesia 25
JO - Giordania 23
PL - Polonia 23
RO - Romania 23
PE - Perù 22
KE - Kenya 21
CH - Svizzera 18
EG - Egitto 18
DZ - Algeria 16
CR - Costa Rica 15
AE - Emirati Arabi Uniti 14
JM - Giamaica 14
UY - Uruguay 14
DK - Danimarca 13
NP - Nepal 13
ET - Etiopia 12
AZ - Azerbaigian 11
OM - Oman 11
PS - Palestinian Territory 10
TH - Thailandia 9
NI - Nicaragua 8
TT - Trinidad e Tobago 8
AL - Albania 7
GT - Guatemala 7
HN - Honduras 7
IL - Israele 7
LB - Libano 7
AU - Australia 6
CZ - Repubblica Ceca 6
KZ - Kazakistan 6
LT - Lituania 6
PT - Portogallo 6
BG - Bulgaria 5
DO - Repubblica Dominicana 5
GE - Georgia 5
KW - Kuwait 5
BB - Barbados 4
BE - Belgio 4
HU - Ungheria 4
IR - Iran 4
LK - Sri Lanka 4
NG - Nigeria 4
PA - Panama 4
SN - Senegal 4
SY - Repubblica araba siriana 4
TG - Togo 4
TW - Taiwan 4
AM - Armenia 3
AO - Angola 3
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
EU - Europa 3
GA - Gabon 3
HR - Croazia 3
KG - Kirghizistan 3
LV - Lettonia 3
SV - El Salvador 3
BA - Bosnia-Erzegovina 2
BT - Bhutan 2
Totale 26.408
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 2.029
Hanoi 1.664
Singapore 1.340
Hong Kong 1.168
San Jose 743
Hefei 700
Ashburn 659
Milan 443
Seoul 298
Ann Arbor 259
Los Angeles 246
Chicago 242
Da Nang 197
Lauterbourg 188
Rome 183
Haiphong 175
Beijing 173
Council Bluffs 167
The Dalles 158
New York 155
Dallas 149
Quận Bình Thạnh 140
Buffalo 132
Ha Long 128
Fairfield 126
Frankfurt am Main 126
São Paulo 124
Biên Hòa 121
Toronto 110
Vũng Tàu 108
Woodbridge 108
Ninh Bình 104
Santa Clara 97
Quận Một 95
Chandler 94
Thái Nguyên 91
Hải Dương 89
Bắc Ninh 82
Dublin 82
Houston 81
Jakarta 79
Seattle 77
Helsinki 75
Can Tho 72
Nuremberg 68
Moscow 67
Boardman 63
Wilmington 62
Rio de Janeiro 61
Phủ Lý 57
Quận Phú Nhuận 53
Baghdad 52
Turin 50
Vinh 49
Bắc Giang 45
Lappeenranta 45
Shanghai 44
Jacksonville 42
Mexico City 41
Quito 39
Dearborn 38
Tashkent 38
Thái Bình 38
Cambridge 37
Quận Tân Phú 37
Guangzhou 36
Quận Sáu 35
Paris 34
Lang Son 32
Naples 32
Curitiba 31
Lấp Vò 31
Vienna 31
Vĩnh Tường 31
Princeton 30
Brasília 29
Dhaka 29
Asunción 28
Figino 28
Thu Dau Mot 28
Tokyo 28
Atlanta 27
Guayaquil 27
Hòa Bình 27
Kent 27
Munich 27
Nam Định 26
Điện Bàn 26
Phoenix 24
Quảng Ninh 24
Quận Năm 24
Belo Horizonte 23
Brooklyn 23
Cà Mau 23
Johannesburg 23
Porto Alegre 23
Nanjing 22
Quận Bốn 22
Quận Hai 22
Riyadh 22
Totale 15.658
Salva come PNG Salva come JPEG
Nome #
Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study 792
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 622
Short commentaries on data published by Petit et al. on locoregional risk after lipofilling in breast cancer patients 552
Analysis of SEMA6B gene expression in breast cancer: Identification of a new isoform 515
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 451
Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study 381
No correlation between plasma D-dimer levels and lymph node involvement in operable breast cancer 374
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 349
A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression 345
Targeting triple negative breast cancer: Is p53 the answer? 343
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy 327
Management and Survival of Pleural Mesothelioma: A Record Linkage Study 304
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival 294
Retinoids and breast cancer: from basic studies to the clinic and back again 287
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 286
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study 262
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer 257
Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study 247
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. 241
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 235
Trastuzumab-related cardiotoxicity in early breast cancer: A cohort study 228
Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway 227
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 220
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 215
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 203
Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists 200
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 198
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 193
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates 191
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems 189
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors 187
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 186
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 185
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 185
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer 183
ACUTE UPPER GASTROINTESTINAL BLEEDING (AUGB) IN ITALY: AN INTERIM ANALYSIS OF THE ORGANIZATIONAL ASPECTS CARING AN EVOLVING DISEASE 180
A network-based data integration approach to support drug repurposing and multi-Target therapies in triple negative breast cancer 179
Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial) 172
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses 171
Transfusion Strategy and Death Risk in Patients with Acute Non-Variceal Upper Gastro Intestinal Bleeding (NV-UGIB) in Italy: A Prospective Multicenter Observational Study 170
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer 168
BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork 165
Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations 165
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 163
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel 161
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry 160
Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer 159
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy 158
Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 154
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients 152
Tyrosine kinase inhibitors and QTc intervals: A class effect 152
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients 150
ONCO-i2b2: improve patients selection through CBR techniques with heterogeneous distance functions 149
Empowering beyond Pain: Pain Neuroscience Education Interventions in Breast Cancer Survivorship Care 149
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 146
Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool 145
Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies 143
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 142
Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al 142
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 138
The central role of pathology labs in breast cancer precision oncology: a call for action 137
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer - Immun-HER trial (GOIRC-01-2016) 137
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 137
i2b2 to optimize patients enrollment 136
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 136
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 136
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction 135
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study 132
The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [18F]FDG PET: Preliminary Results from a Prospective Cohort 130
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis 130
Correction to: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors (Journal of Endocrinological Investigation, (2023), 47, 2, (433-442), 10.1007/s40618-023-02174-5) 129
The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question 129
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy 128
COVID-19 Sequelae and the Host Pro-Inflammatory Response: An Analysis From the OnCovid Registry 127
Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study 126
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 125
Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study 125
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 123
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 123
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 123
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 120
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants 119
Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527](S1040842824002701)(10.1016/j.critrevonc.2024.104527) 117
Clinical Review on the Management of Breast Cancer Visceral Crisis 117
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 116
Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis 114
Evolving phenotypes of non-hospitalized patients that indicate long COVID 113
International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality 113
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 113
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 112
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review 112
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 111
The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy 111
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 111
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium 108
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 107
HGF/c-met signalling in the tumor microenvironment 107
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 106
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy 106
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors 105
Totale 19.229
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.004
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.004
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022201 17 23 36 12 4 13 5 8 8 21 25 29
2022/2023357 35 123 36 22 22 49 0 22 22 1 15 10
2023/2024213 5 6 11 8 32 50 42 8 19 0 7 25
2024/20254.752 31 74 15 28 60 646 313 116 318 644 455 2.052
2025/202620.025 4.958 3.266 1.345 2.022 831 530 1.557 763 1.050 1.195 828 1.680
2026/2027527 527 0 0 0 0 0 0 0 0 0 0 0
Totale 27.122